Blurbs

Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on SCYNEXIS (SCYX)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on SCYNEXIS (SCYXResearch Report), with a price target of $15.00. The company’s shares closed yesterday at $1.80.

Higgins covers the Healthcare sector, focusing on stocks such as Palatin Technologies, SCYNEXIS, and Eiger Biopharmaceuticals. According to TipRanks, Higgins has an average return of 2.9% and a 28.57% success rate on recommended stocks.

Currently, the analyst consensus on SCYNEXIS is a Strong Buy with an average price target of $9.50.

See Insiders’ Hot Stocks on TipRanks >>

SCYX market cap is currently $73.14M and has a P/E ratio of -1.13.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Read More on SCYX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More